Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients.

Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.]

Proteasome inhibitors for multiple myeloma.

Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108.

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.

Abramson HN. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.015. [Epub 2018 Jun 18.]

FDG PET-CT in Adrenal Multiple Myeloma.

Choudhury S et al. Clin Nucl Med. 2018 Sep. doi: 10.1097/RLU.0000000000002195.

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.

Dinner S et al. Int J Hematol. 2018 Sep. doi: 10.1007/s12185-018-2468-5.

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E et al. Ann Hematol. 2018 Sep. doi: 10.1007/s00277-018-3361-2.